Cargando…

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Tian, Zhuang, Li, Sun, Xiao-Dong, Qi, Xiao-Sheng, Wang, Zhi-Hui, Li, Rui-Dong, Chang, Wen-Xiu, Yang, Jia-Yin, Yang, Yang, Zheng, Shu-Sen, Xu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385566/
https://www.ncbi.nlm.nih.gov/pubmed/32774062
http://dx.doi.org/10.3748/wjg.v26.i27.3851
_version_ 1783563811217735680
author Shen, Tian
Zhuang, Li
Sun, Xiao-Dong
Qi, Xiao-Sheng
Wang, Zhi-Hui
Li, Rui-Dong
Chang, Wen-Xiu
Yang, Jia-Yin
Yang, Yang
Zheng, Shu-Sen
Xu, Xiao
author_facet Shen, Tian
Zhuang, Li
Sun, Xiao-Dong
Qi, Xiao-Sheng
Wang, Zhi-Hui
Li, Rui-Dong
Chang, Wen-Xiu
Yang, Jia-Yin
Yang, Yang
Zheng, Shu-Sen
Xu, Xiao
author_sort Shen, Tian
collection PubMed
description Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases.
format Online
Article
Text
id pubmed-7385566
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-73855662020-08-07 Expert consensus on management of metabolic disease in Chinese liver transplant recipients Shen, Tian Zhuang, Li Sun, Xiao-Dong Qi, Xiao-Sheng Wang, Zhi-Hui Li, Rui-Dong Chang, Wen-Xiu Yang, Jia-Yin Yang, Yang Zheng, Shu-Sen Xu, Xiao World J Gastroenterol Guidelines Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases. Baishideng Publishing Group Inc 2020-07-21 2020-07-21 /pmc/articles/PMC7385566/ /pubmed/32774062 http://dx.doi.org/10.3748/wjg.v26.i27.3851 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Guidelines
Shen, Tian
Zhuang, Li
Sun, Xiao-Dong
Qi, Xiao-Sheng
Wang, Zhi-Hui
Li, Rui-Dong
Chang, Wen-Xiu
Yang, Jia-Yin
Yang, Yang
Zheng, Shu-Sen
Xu, Xiao
Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title_full Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title_fullStr Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title_full_unstemmed Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title_short Expert consensus on management of metabolic disease in Chinese liver transplant recipients
title_sort expert consensus on management of metabolic disease in chinese liver transplant recipients
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385566/
https://www.ncbi.nlm.nih.gov/pubmed/32774062
http://dx.doi.org/10.3748/wjg.v26.i27.3851
work_keys_str_mv AT shentian expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT zhuangli expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT sunxiaodong expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT qixiaosheng expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT wangzhihui expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT liruidong expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT changwenxiu expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT yangjiayin expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT yangyang expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT zhengshusen expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients
AT xuxiao expertconsensusonmanagementofmetabolicdiseaseinchineselivertransplantrecipients